NISCH
Nischarin
As of the edition of 20 October 2026, NISCH (nischarin, UniProt Q9Y2I1) has 2 drugs tested at it and 0 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9Y2I1
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 2
- Disease areas
- Heart and blood vessels; Nutrition and metabolism; Nervous system; Pregnancy and women's health; Urinary and reproductive; Bones, joints and muscles; Hormones; Mental health
- Registered trials of its drugs
- 16
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Moxonidine | Marketed | Phase 4 | none listed |
| Rilmenidine | Marketed | Phase 4 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Total on the list | 0 |